Diabetic Kidney Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight

What impact are companies like Daiichi Sankyo, Prokidney, AstraZeneca, and Palatin having on the evolution of the Diabetic Kidney Disease market?

LAS VEGAS , NV, UNITED STATES, December 3, 2024 /EINPresswire.com/ -- DelveInsight’s “Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Diabetic Kidney Disease, historical and forecasted epidemiology as well as the Diabetic Kidney Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Diabetic Kidney Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here; Diabetic Kidney Disease Market Forecast Report

Some of the key facts of the Diabetic Kidney Disease Market Report:

The total market size for Diabetic Kidney Disease (DKD) in the 7MM was approximately USD 6.5 billion in 2023, with projected growth during the forecast period (2024–2034).
The prevalent cases of diabetes in the 7MM totaled approximately 82K cases in 2023 and are expected to rise during the forecast period.
The total prevalent cases of DKD in the 7MM were around 33K cases in 2023, with a projected increase by 2034.
Among the 7MM, the United States had the highest number of diagnosed prevalent cases of DKD, accounting for about 45% of the total cases in 2023.
In May 2023, Reata Pharmaceuticals terminated the FALCON and EAGLE clinical trials of bardoxolone methyl, as no safety issues were identified by the Data Monitoring Committee (DMC).
Key Diabetic Kidney Disease Companies: Daiichi Sankyo, Prokidney, AstraZeneca, Palatin, Chinook Therapeutics, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.
Key Diabetic Kidney Disease Therapies: REACT, Esaxerenone, SER150, Atrasentan, Zibotentan, BI 690517 ± empagliflozin, Lorundrostat ± Dapagliflozin, VYLEESI, INV-202, BAY1142524, and others.
The DKD market is expected to grow during the forecast period due to increasing prevalence and awareness, with the launch of multiple-stage therapies significantly shaping market dynamic

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD), or diabetic nephropathy, is a condition marked by persistent albuminuria and a gradual decline in kidney function, often linked to hypertension and increased cardiovascular risks. The primary cause is hyperglycemia, though other factors may contribute. In the early stages, symptoms may not be present, but as kidney function worsens, toxic waste builds up, leading to nausea, loss of appetite, weight gain from fluid retention, and hiccups. If untreated, DKD can result in heart failure and fluid buildup in the lungs.

Diabetic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Kidney Disease Epidemiology Segmentation:

The Diabetic Kidney Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total prevalent cases of diabetes
Total diagnosed prevalent cases of diabetes
Total prevalent cases of DKD, age-specific cases of DKD
Stage-specific cases of DKD

Diabetic Kidney Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Kidney Disease market or expected to be launched during the study period. The analysis covers the market uptake of Diabetic Kidney Disease by drugs, patient uptake by therapies, and drug sales.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Diabetic Kidney Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Kidney Disease Therapies and Key Companies

REACT: PROKIDNEY
Esaxerenone: AstraZeneca
SER150: Serodus
Atrasentan: Chinook Therapeutics
Zibotentan + dapagliflozin: AstraZeneca
BI 690517 ± empagliflozin: Boehringer Ingelheim
Lorundrostat ± Dapagliflozin: Mineralys Therapeutics
VYLEESI: Palatin
INV-202: INVERSAGO PHARMA
BAY1142524: Bayer.

Discover more about therapies set to grab major Diabetic Kidney Disease market share @ Diabetic Kidney Disease Treatment Landscape

Scope of the Diabetic Kidney Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Diabetic Kidney Disease Companies: Daiichi Sankyo, Prokidney, AstraZeneca, Palatin, Chinook Therapeutics, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.
Key Diabetic Kidney Disease Therapies: REACT, Esaxerenone, SER150, Atrasentan, Zibotentan, BI 690517 ± empagliflozin, Lorundrostat ± Dapagliflozin, VYLEESI, INV-202, BAY1142524, and others.
Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers.
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Diabetic Kidney Disease Unmet Needs, KOL’s views, Analyst’s views, Diabetic Kidney Disease Market Access and Reimbursement

Table of Contents

1. Diabetic Kidney Disease Market Report Introduction
2. Executive Summary for Diabetic Kidney Disease
3. SWOT analysis of Diabetic Kidney Disease
4. Diabetic Kidney Disease Patient Share (%) Overview at a Glance
5. Diabetic Kidney Disease Market Overview at a Glance
6. Diabetic Kidney Disease Disease Background and Overview
7. Diabetic Kidney Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Diabetic Kidney Disease
9. Diabetic Kidney Disease Current Treatment and Medical Practices
10. Diabetic Kidney Disease Unmet Needs
11. Diabetic Kidney Disease Emerging Therapies
12. Diabetic Kidney Disease Market Outlook
13. Country-Wise Diabetic Kidney Disease Market Analysis (2020–2034)
14. Diabetic Kidney Disease Market Access and Reimbursement of Therapies
15. Diabetic Kidney Disease Market Drivers
16. Diabetic Kidney Disease Market Barriers
17. Diabetic Kidney Disease Appendix
18. Diabetic Kidney Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Diabetic Kidney Disease Pipeline Report

DelveInsight's 'Diabetic Kidney Disease - Pipeline Insight, 2024' report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Diabetic Kidney Disease companies, including Daiichi Sankyo, ProKidney, AstraZeneca, Palatin, Chinook Therapeutics, Novartis, and Mineralys Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Jatin Vimal
DelveInsight Business Research LLP
+1 469-945-7679
info@delveinsight.com